Future Clinical Trials: Genetically Driven Trials

Igor Astsaturov

doi:10.1016/j.soc.2017.05.014

Future Clinical Trials: Genetically Driven Trials

Igor Astsaturov

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The design of modern oncology clinical trials seeks to match patients’ cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs’ activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.

Original language	English
Pages (from-to)	791-797
Number of pages	7
Journal	Surgical Oncology Clinics of North America
Volume	26
Issue number	4
DOIs	https://doi.org/10.1016/j.soc.2017.05.014
State	Published - Oct 2017

Keywords

Biomarkers, Tumor/genetics
Humans
Medical Oncology/methods
Molecular Targeted Therapy/methods
Neoplasms/diagnosis
Pharmacogenetics
Precision Medicine/trends
Treatment Outcome

Access to Document

10.1016/j.soc.2017.05.014

Cite this

@article{e94ad4d316e34ecc8ad1948a1d346bdb,

title = "Future Clinical Trials: Genetically Driven Trials",

abstract = "The design of modern oncology clinical trials seeks to match patients{\textquoteright} cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs{\textquoteright} activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.",

keywords = "Biomarkers, Tumor/genetics, Humans, Medical Oncology/methods, Molecular Targeted Therapy/methods, Neoplasms/diagnosis, Pharmacogenetics, Precision Medicine/trends, Treatment Outcome",

author = "Igor Astsaturov",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.soc.2017.05.014",

language = "English",

volume = "26",

pages = "791--797",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Future Clinical Trials

T2 - Genetically Driven Trials

AU - Astsaturov, Igor

PY - 2017/10

Y1 - 2017/10

N2 - The design of modern oncology clinical trials seeks to match patients’ cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs’ activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.

AB - The design of modern oncology clinical trials seeks to match patients’ cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs’ activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.

KW - Biomarkers, Tumor/genetics

KW - Humans

KW - Medical Oncology/methods

KW - Molecular Targeted Therapy/methods

KW - Neoplasms/diagnosis

KW - Pharmacogenetics

KW - Precision Medicine/trends

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85027543498&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000412969600017&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.soc.2017.05.014

DO - 10.1016/j.soc.2017.05.014

M3 - Review article

C2 - 28923231

SN - 1055-3207

VL - 26

SP - 791

EP - 797

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 4

ER -

Future Clinical Trials: Genetically Driven Trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this